2-chloropyrazine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 73277 |
| CHEMBL ID | 1741693 |
| CHEBI ID | 95323 |
| SCHEMBL ID | 6771 |
| MeSH ID | M0538217 |
| Synonym |
|---|
| AC-2454 |
| EN300-21095 |
| BRD-K84075000-001-03-0 |
| 14508-49-7 |
| PRESTWICK3_001087 |
| chloropyrazine |
| NCGC00016707-01 |
| cas-14508-49-7 |
| BPBIO1_001248 |
| inchi=1/c4h3cln2/c5-4-3-6-1-2-7-4/h1-3 |
| pyrazine, 2-chloro- |
| 2-chloropyrazine |
| AB00514039 |
| PRESTWICK2_001087 |
| BSPBIO_001134 |
| 2-chloropyrazine, 97% |
| PRESTWICK0_001087 |
| PRESTWICK1_001087 |
| SPBIO_003027 |
| NCGC00016707-02 |
| HMS1571I16 |
| AKOS000121584 |
| HMS2098I16 |
| 2-chloro-pyrazine |
| STL163428 |
| BBL011919 |
| AM803218 |
| pyrazine, chloro- |
| einecs 238-517-0 |
| BP-12074 |
| FT-0601046 |
| FT-0649350 |
| CCG-221087 |
| SCHEMBL6771 |
| 2- chloropyrazine |
| chioropyrazine |
| chloro-pyrazine |
| chloropyrazin |
| 2-chloro pyrazine |
| 6-chloropyrazine |
| DTXSID0065779 |
| W-108142 |
| CHEMBL1741693 |
| STR02733 |
| PS-9235 |
| mfcd00006124 |
| F2173-0204 |
| sr-01000872682 |
| SR-01000872682-1 |
| CHEBI:95323 |
| CS-W018537 |
| Q27167194 |
| BCP26699 |
| HY-Y0109 |
| Z104490192 |
| Class | Description |
|---|---|
| pyrazines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (38.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||